A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)

Cerevel Therapeutics, LLC0 个研究点目标入组 522 人开始时间: 2020年2月28日最近更新: 2020年5月11日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Cerevel Therapeutics, LLC
入组人数: 522

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.,Male and female subjects aged 40 to 80 years, inclusive, at the time of signing the ICF.
•2.,Sexually active men or women of childbearing potential must agree to practice effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
•3.,Subjects who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
•4.,Subjects who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
•5.,Subjects with a diagnosis of that is consistent with the UK Parkinson’s Disease Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry
•6.,Subjects with modified Hoehn and Yahr stage 1, 1.5, or 2.
•7.,Subjects with disease duration (from time of diagnosis) of <3 years and disease progression in the 3 years before signing the ICF.
•8.,Subjects with an MDS UPDRS Part II score =2 and Part III score =10 at the Screening Visit.
•9.,Subjects with early PD who, in the opinion of the investigator, require pharmacologic intervention for disease management.
•10.,Subjects who are treatment naïve or have a history of prior incidental treatment with dopaminergic agents (including L-Dopa and dopamine receptor agonist medications) for <3 months and not within 2 months of signing the ICF. Prior and concurrent use of MAO B inhibitors is permitted if use was initiated >90 days before signing of the ICF and the dosage will remain stable for the duration of the trial (ie, no change in the MAO B inhibitor dose is permitted during the trial).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 322

排除标准

•1.,Subjects with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug induced or poststroke parkinsonism).
•2. Subjects with a history of nonresponse or insufficient response to L-Dopa or 2 or more other antiparkinsonian drugs at therapeutic dosages.
•3.,Subjects who have had previous surgical intervention (eg, deep brain stimulation) for PD or for whom such a procedure is planned or anticipated during the trial period.
•4.,Subjects with an acute or chronic, clinically significant medical or psychiatric condition, cognitive impairment, or laboratory abnormality that might increase the risk associated with trial participation or administration of trial treatment or interfere with the interpretation of the trial results or that, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
•Medical conditions that are minor or well controlled may be considered acceptable if the condition does not expose the subject to an undue risk of a significant AE or interfere with the assessments of safety or efficacy during the course of the trial. Subjects with symptoms of anxiety or depression that are not debilitating and that are stable or adequately controlled with non-prohibited medication are considered acceptable. The medical monitor should be contacted in any instance where the investigator is uncertain regarding the stability of a subject’s medical conditions(s) and the potential impact of the condition(s) on trial participation.
•5.,Subjects with a history or current diagnosis of a clinically significant impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM 5) (American Psychiatric Association, 2013).
•6.,Subjects with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures
•7.,Subjects with a history of psychosis or hallucinations within the previous 12 months based on medical records or subject/caregiver feedback
•8.,Subjects who answer yes” on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C SSRS Item 4 or Item 5 occurred within the last 6 months, OR
•Subjects who answer yes” on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR
•Subjects who, in the opinion of the investigator, present a serious risk of suicide.
•9.,Subjects with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days).
•10.,Subjects with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the subject from understanding the ICF or participating in the trial.
•11. Subjects with a MoCA score <26.
•12. Subjects who previously participated in any tavapadon trial, including this trial, and received IMP.
•13. Subjects who received treatment with any other investigational drug within 60 days before signing the I

研究者

发起方

Cerevel Therapeutics, LLC

相似试验

进行中（未招募）

1 期

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)Patients (40 to 80 years age) who have diagnosis of Parkinson's DiseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2019-002949-38-DECerevel Therapeutics, LLC522

进行中（未招募）

1 期

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY,AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL)Patients (18 to 60 years age) who have diagnosis of Parkinson's DiseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2019-002949-38-ITCerevel Therapeutics LLC522

进行中（未招募）

1 期

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)Patients (18 to 60 years age) who have diagnosis of Parkinson's DiseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2019-002949-38-CZCerevel Therapeutics, LLC522

进行中（未招募）

1 期

EUCTR2019-002949-38-BGCerevel Therapeutics, LLC522

进行中（未招募）

1 期

EUCTR2019-002949-38-FRCerevel Therapeutics, LLC552